Participant Flow Module
The Participant Flow Module provides information about the flow of participants through each stage of the clinical trial. This includes pre-assignment details, recruitment information, and the types of units analyzed, helping researchers understand how participants move through the study.
Participant Flow Module path is as follows:
Study -> Results Section -> Participant Flow Module
Participant Flow Module
Ignite Creation Date:
2025-12-25 @ 2:14 AM
Ignite Modification Date:
2025-12-26 @ 12:43 AM
NCT ID:
NCT01210560
Pre Assignment Details:
Screening visit, baseline visit, 3 periods - each with 3 treatments in Group 1 \& 2 in one of the sequences DAE, DBE, DCE, EAD, EBD / ECD \& FGH, HFG / GHF (2 \& 4 participants per sequence) respectively; (MR: A\&F= 20mg, B\&G = 20+20mg, C\&H = 60mg, D = 120mg; IR: E = 90+30mg) and 7 Day follow-up. All doses were taken orally once/twice(B\&G) daily.
Recruitment Details:
Study was conducted at 6 centers in the United States. 25 participants were randomized (12+13) to Group 1 \& 2 with 5 \& 3 treatment sequences, respectively; received tolvaptan Modified-release \[MR\] capsules \& Immediate-release \[IR\] tablets in Group 1 \& MR in Group 2 over 3 therapy periods (each 7 days) in parallel-group, crossover design
Study:
NCT01210560
Study Brief:
Results Section:
NCT01210560